{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:45:10Z","timestamp":1748954710090},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/ppo.0b013e31827f123e","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T11:57:06Z","timestamp":1358596626000},"page":"66-70","source":"Crossref","is-referenced-by-count":27,"title":["Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1097","volume":"19","author":[{"given":"Shanna","family":"Rajpar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":". Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":". Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":". Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":". Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-10-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":". Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":". Impact of skeletal complications on patients quality of life, mobility, and functional independence.","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":". A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":". The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":". Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"R13-10-20210203","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":". Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.","volume":"26","author":"Halabi","year":"2008","journal-title":"J Clin Oncol"},{"key":"R15-10-20210203","first-page":"2587","article-title":". Prostate cancer cells-osteoblast interaction shifts expression of growthsurvival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R17-10-20210203","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.","volume":"91","author":"Keller","year":"2004","journal-title":"J Cell Biochem"},{"key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":". Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":". Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects.","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"suppl 1","key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: promising preclinical evidence.","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R24-10-20210203","first-page":"1089","article-title":". Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.","volume":"29","author":"Tanaka","year":"2009","journal-title":"Anticancer Res"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cellbi.2008.11.011","article-title":". Docetaxelzoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic BCL-2 protein level in hormone-refractory prostate cancer cells.","volume":"33","author":"Karabulut","year":"2009","journal-title":"Cell Biol Int"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/02841860510029617","article-title":". Additivesynergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.","volume":"44","author":"Ullen","year":"2005","journal-title":"Acta Oncol"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2407-6-15","article-title":". Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.","volume":"6","author":"Brubaker","year":"2006","journal-title":"BMC Cancer"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":". Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"R29-10-20210203","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":". Breast-cancer adjuvant therapy with zoledronic acid.","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-10-20210203","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":". Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R32-10-20210203","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":". Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"R33-10-20210203","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":". Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"R34-10-20210203","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":". Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"R35-10-20210203","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":". Regulation of cancer cell migration and bone metastasis by RANKL.","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"R36-10-20210203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":". Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"R37-10-20210203","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1200\/JCO.1999.17.3.948","article-title":". Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.","volume":"17","author":"Sabbatini","year":"1999","journal-title":"J Clin Oncol"},{"key":"R39-10-20210203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":". Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R40-10-20210203","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":". Urinary N-telopeptide (uNTX) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"R41-10-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":". Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"R42-10-20210203","first-page":"663","article-title":". Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.","volume":"56","author":"Nelson","year":"1996","journal-title":"Cancer Res"},{"key":"R43-10-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1479-5876-2-16","article-title":"Endothelin receptors as novel targets in tumor therapy.","volume":"2","author":"Bagnato","year":"2004","journal-title":"J Transl Med"},{"key":"R44-10-20210203","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":". A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R45-10-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4161\/cbt.9.8.11112","article-title":"Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.","volume":"9","author":"Drake","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R46-10-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.06388","article-title":". Endothelin receptor A blockade enhances taxane effects in prostate cancer.","volume":"8","author":"Akhavan","year":"2006","journal-title":"Neoplasia"},{"key":"R47-10-20210203","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/cncr.27674","article-title":". Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.","volume":"118","author":"Nelson","year":"2012","journal-title":"Cancer"},{"key":"R49-10-20210203","first-page":"249","article-title":"Dosage and response in radiopharmaceutical therapy of painful osseous metastases.","volume":"37","author":"Silberstein","year":"1996","journal-title":"J Nucl Med"},{"key":"R51-10-20210203","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":". A prospective, randomised double-blind crossover study to examine the efficacy of strontium- 89 in pain palliation in patients with advanced prostate cancer metastatic to bone.","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"R52-10-20210203","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":". Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R53-10-20210203","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":". Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"key":"R54-10-20210203","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":". Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"R55-10-20210203","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":". Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R57-10-20210203","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"SRC family kinases in tumor progression and metastasis.","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"R58-10-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.23998","article-title":"Targeting SRC signaling in metastatic bone disease.","volume":"124","author":"Araujo","year":"2009","journal-title":"Int J Cancer"},{"key":"R59-10-20210203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/annonc\/mdm086","article-title":"The role of SRC in prostate cancer.","volume":"18","author":"Fizazi","year":"2007","journal-title":"Ann Oncol"},{"key":"R60-10-20210203","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","article-title":". Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"R61-10-20210203","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":". The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R62-10-20210203","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/1078-0432.CCR-08-1857","article-title":". SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.","volume":"15","author":"Tatarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R63-10-20210203","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":". Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"R64-10-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":". Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"key":"R65-10-20210203","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":". Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"R66-10-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":". Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"R67-10-20210203","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":". Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00130404-201301000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:56:55Z","timestamp":1618037815000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201301000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31827f123e","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}